

<b>Risk Category/Disease and Stage*</b>	<b>MMF (n = 74)</b>	<b>Placebo (n = 77)</b>
<b>Low risk of recurrent disease, n (%)</b>	<b>50 [8,4]<sup>†</sup> (68)</b>	<b>52 [3,3] (68)</b>
Sickle cell disease	0 [0,0] (0)	1 [0,0] (1)
Myeloproliferative disorders or myelofibrosis	4 [2,0] (5)	3 [0,0] (4)
Chronic myeloid leukemia in chronic phase	3 [0,1] (4)	2 [0,0] (3)
Refractory anemia	5 [0,0] (7)	3 [0,0] (4)
Chronic lymphocytic leukemia	4 [1,0] (5)	3 [0,0] (4)
Acute leukemia	29 [3,3] (39)	26 [1,3] (34)
Lymphoma	2 [1,0] (3)	8 [1,0] (10)
Myeloma	3 [1,0] (4)	6 [1,0] (8)
<b>High risk of recurrent malignancy, n (%)</b>	<b>24 [9,4] (32)</b>	<b>25 [7,2] (32)</b>
Chronic myeloid leukemia in accelerated phase	2 [0,1] (3)	1 [0,0] (1)
Chronic myelomonocytic leukemia	1 [1,0] (1)	1 [1,0] (1)
Refractory anemia with excess blasts	10 [5,1] (14)	9 [3,0] (12)
Acute leukemia	11 [3,2] (15)	12 [3,2] (16)
Lymphoma	0 (0)	2 [0,0] (3)

\* Categories correspond with low and standard risk of recurrent malignancy versus high risk of recurrent malignancy, as defined by Kahl et al.<sup>32</sup>

<sup>†</sup> [x,x] = [no. of relapses, no. of non-relapse deaths]